US EditionAssociation of ADAM Family Members with Proliferation Signaling and Disease Progression in Multiple Myeloma
6 Articles
6 Articles
Association of ADAM family members with proliferation signaling and disease progression in multiple myeloma
Multiple myeloma (MM) is a hematological malignancy whose curability is greatly challenged by recurrent patient relapses and therapy resistance. We have previously proposed the high expression of ADAM8, ADAM9 and ADAM15 (A Disintegrin And Metalloproteinase 8/9/15) as adverse prognostic markers in MM. This study focused on the so far scarcely researched role of ADAM8/9/15 in MM using two patient cohorts and seven human MM cell lines (HMCL). High …
Two new studies offer a glimmer of hope to patients with multiple myeloma, a particularly merciless form of blood cancer, learned early in the Canadian Press.
MONTREAL — Two new studies offer a glimmer of hope to patients with multiple myeloma, a particularly merciless form of blood cancer, learned early in the Canadian Press. The first study showed that the treatment of Carvykti immunotherapy allowed one third of patients with relapsed or refractory multiple myeloma to achieve progression-free survival of five years or more after a single infusion. The second study revealed an improvement in progress…
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
To view factuality data please Upgrade to Premium